Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 6/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 8/20 | 0.53 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.51 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.51 |
| ▸ | GGH | Q92820 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1834431 | 1.00 | NAALAD2 (0.56) | NAALAD2GAAFOLH1RIMKLASLC1A3 | |
| SCHEMBL5262634 | 0.88 | KMT2A (0.57) | NAALAD2GAASLC1A3MMP9 | |
| SCHEMBL5262631 | 0.88 | KMT2A (0.57) | NAALAD2GAASLC1A3MMP9 | |
| SCHEMBL4654152 | 0.87 | FOLH1 (0.47) | NAALAD2GAAFOLH1RIMKLA | |
| SCHEMBL4654148 | 0.87 | FOLH1 (0.47) | NAALAD2GAAFOLH1RIMKLA | |
| SCHEMBL13610482 | 0.85 | NAALAD2 (0.49) | NAALAD2GAAFOLH1RIMKLA | |
| SCHEMBL31663461 | 0.84 | MMP2 (0.52) | SLC1A3MMP9MMP8 | |
| SCHEMBL21802397 | 0.84 | SLC1A3 (0.54) | GAASLC1A3 | |
| SCHEMBL21802396 | 0.84 | SLC1A3 (0.54) | GAASLC1A3 | |
| SCHEMBL8477195 | 0.82 | FOLH1 (0.50) | NAALAD2GAAFOLH1RIMKLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166087-B | Screening agent and use thereof | 恩多塞特公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-110546135-B | Method for producing isocyanate | 旭化成株式会社 | 2021-12-14 | — | — | CN | disclosed |
| CN-112438905-B | Moisturizing and skin-brightening composition and application thereof | 澳思美日用化工（广州）有限公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-113166087-A | Shielding agent and application thereof | 恩多塞特公司 | 2021-07-23 | — | — | CN | disclosed |
| US-10968168-B2 | Isocyanate production method | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2021-04-06 | — | — | US | disclosed |
| EP-3626705-B1 | ISOCYANATE PRODUCTION METHOD | ASAHI CHEMICAL IND (JP) | 2021-03-24 | — | — | EP | disclosed |
| CN-112438905-A | Moisturizing and skin-brightening composition and application thereof | 澳思美日用化工（广州）有限公司 | 2021-03-05 | — | — | CN | disclosed |
| US-20200115327-A1 | ISOCYANATE PRODUCTION METHOD | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-04-16 | — | — | US | disclosed |
| EP-3626705-A1 | ISOCYANATE PRODUCTION METHOD | Asahi Kasei Kabushiki Kaisha (JP) | 2020-03-25 | — | — | EP | disclosed |
| CN-110546135-A | Method for producing isocyanate | ASAHI CHEMICAL IND | 2019-12-06 | — | — | CN | disclosed |
| CN-101327226-A | Light-emitting microorganisms and cells for tumour diagnosis/therapy | GENELUX CORP (US) | 2008-12-24 | — | — | CN | disclosed |
| EP-1338588-B1 | METHOD OF RESOLVING OPTICAL ISOMERS OF AMINO ACID DERIVATIVE | TOKUYAMA CORP (JP) | 2007-09-26 | — | — | EP | disclosed |
| US-7199264-B2 | Method of resolving optical isomers of amino acid derivative | TOKUYAMA CORPORATION (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040102646-A1 | Method of resolving optical isomers of amino acid derivative | TOKUYAMA CORPORATION (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1338588-A1 | METHOD OF RESOLVING OPTICAL ISOMERS OF AMINO ACID DERIVATIVE | TOKUYAMA CORPORATION (JP) | 2003-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102646-A1 | Method of resolving optical isomers of amino acid derivative | ALAD, AAAS, BCAT1 | NAALAD2 69/4885GAA 2087/4885FOLH1 1171/4885 |
| US-20200115327-A1 | ISOCYANATE PRODUCTION METHOD | IDH3A, ALKBH3, CPS1 | NAALAD2 208/4885GAA 1174/4885FOLH1 1222/4885 |
| US-10968168-B2 | Isocyanate production method | IDH3A, ALKBH3, CPS1 | NAALAD2 208/4885GAA 1174/4885FOLH1 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.